Targeted radiation for a small number of sarcoma metastases
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tests a highly focused radiation treatment to shrink sarcoma that has spread to a limited number of spots in the body. It may help control disease while limiting radiation to healthier tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have soft tissue sarcoma (examples include uterine/extra-uterine leiomyosarcoma, liposarcoma, or undifferentiated sarcoma).
- Your disease is getting worse on scans, and you have 1 to 5 visible metastases that can be seen on CT.
- You are 18 years or older and can do usual activities at a basic level (ECOG 0–1).
- At least one tumor spot to treat is small enough (measurable and under 5 cm).
- Your blood counts and organs (kidneys, liver, bilirubin) are strong enough for treatment based on recent lab tests.
- You can safely take part in a study that involves pregnancy prevention if applicable (and you must not be pregnant or breastfeeding).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
This trial tests a new type of radiation called spatially fractionated radiation therapy (SFRT) given before surgery for large soft tissue sarcomas in the arm, leg, or trunk. The goal is to see if it helps shrink the tumor and improve treatment outcomes.
This study tests a combination of chemo medicines (gemcitabine, doxorubicin, docetaxel) plus an immunotherapy drug (nivolumab) for advanced sarcoma that can’t be removed with surgery. It may help shrink tumors and slow disease growth in people whose cancer has already been treated and is measurable on scans.
This trial tests whether combining an immunotherapy drug (atezolizumab) with focused radiation and surgery can help people whose osteosarcoma has come back only in the lungs. It aims to see if this approach is safe and may improve outcomes.
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
This Phase 1/2 trial tests whether combining radiation with two targeted/immune medicines can shrink or control high-risk soft tissue sarcoma and improve outcomes. It may help patients whose tumors are large, hard to fully remove, or have come back after prior treatment.
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.